Alan Tan

They can't button their shirts.

How you guys...

Managing that, are you guys de-escalating therapy somehow based on anything?

Are you guys following ctDNA on those patients?

Yeah, I'm certainly a believer.

Just, you know, I'm doing this as a correlative at our center.

And I think if people don't clear their ctDNA by six cycles, they're in trouble.

They're in trouble.

And what do I see under NGS reports when they haven't cleared ctDNA or maybe their ctDNA can start going up?

Well, it's the usual suspects.

FGFR mutation, ERBP2 alteration, MTAP is in man-invention.

So, yeah, I think, you know, we need to do more work there as academic centers and look retrospectively and say, who are these resistant populations?

Because pharma is definitely interested in combining.

And Brad, you know, you've done some studies with dual antibody drug conjugates, right?

DADEO.

Tell me more about that.

Yeah, I mean, as Amanda mentioned, like the payload, I mean, DV data looks amazing in the metastatic setting and in the perioperative setting.

Not sure about the CR rates that the Chinese data supported.

That was kind of unusual.

But it's unfortunate that the payload is the same thing, MMAE.